Positron Emission Tomography News and Research

RSS

Patient-relevant benefit of PET or PET/CT in oesophageal cancer is still unclear

The patient-relevant benefit of positron emission tomography (PET) in oesophageal cancer, alone or in combination with computed tomography (CT), is not proven due to a lack of comparative studies. In terms of their diagnostic and prognostic accuracy, it also remains unclear whether these diagnostic techniques can detect the spreading of tumours better than conventional diagnostics.

29 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Dopamine responses to alcohol ingestion may serve as marker of vulnerability to AUDs

There are two traits closely associated with the development of alcohol use disorders (AUDs). One is a lower subjective intoxication response, also known as a low level of response to alcohol.

12 Aug 2013

Alcohol use increases risk of dopamine response in brain pathway

Research from McGill University suggests that people who are vulnerable to developing alcoholism exhibit a distinctive brain response when drinking alcohol, according to a new study by Prof. Marco Leyton, of McGill University's Department of Psychiatry.

3 Aug 2013

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma-a key factor in tailoring patient management plans-has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine.

2 Aug 2013

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has received a $500,000 order for its patented Lutetium Fine Silicate (LFS) scintillation crystals from its strategic partner Hamamatsu Photonics (Tokyo: 6965) of Japan.

31 Jul 2013

Glucose intolerance, insulin resistance not associated with pathological features of AD

Glucose intolerance or insulin resistance do not appear to be associated with pathological features of Alzheimer disease (AD) or detection of the accumulation of the brain protein β-amyloid (Αβ), according to a report published by JAMA Neurology, a JAMA Network publication.

30 Jul 2013

Long-term cannabis use, dopamine and motivation: an interview with Dr Michael Bloomfield, Department of Medicine at Imperial

We classified ‘long-term’ cannabis use as being regular, at least weekly, cannabis use for over 12 months. This is the period of time that’s used in the DSM-IV psychiatric diagnostic manual to classify substance use disorders. In our study the average duration of at least weekly use was just over four and a half years.

17 Jul 2013

Zecotek partners with Hamamatsu to commercialize existing imaging technologies

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that its wholly owned subsidiary Zecotek Imaging Systems Pte. Ltd. has signed a joint collaboration partnership agreement with Hamamatsu Photonics (Tokyo: 6965) of Japan to commercialize existing imaging technologies and to collaborate on the upgrade and manufacture of photo detectors, integrated detector modules (IDM) and associated electronics and data acquisition modules for the imaging markets at large.

16 Jul 2013

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.

11 Jul 2013

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

Eli Lilly and Company today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a draft decision proposing Coverage with Evidence Development for the use of beta-amyloid positron emission tomography (PET) imaging agents. Beta-amyloid imaging agents are used to evaluate patients with cognitive impairment for Alzheimer's Disease and other causes of cognitive decline.

5 Jul 2013

Pretreatment PET staging of LS-SCLC associated with improved survival

Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer is only present in one lung, but may have spread to lymph nodes or tissue between the lungs.

26 Jun 2013

Study finds PTSD as risk factor for heart disease among Vietnam vets

Male twin Vietnam veterans with post-traumatic stress disorder were more than twice as likely as those without PTSD to develop heart disease during a 13-year period, according to a study supported by the National Institutes of Health.

26 Jun 2013

Radionuclide drug treatment planning goes to next level with 3-D patient models

External beam radiation treatment has long been manipulated into the unique shape of patients' tumors for personalized cancer care. Technology providing a means of patient-specific radionuclide drug therapies has not been standardized, as it has been limited to software that requires oncologists to manually define the areas of tumors.

13 Jun 2013

Researcher improves segmentation technique of PET images

Elena Prieto-Azkarate, a graduate in Telecommunications Engineering at the NUP/UPNA-Public University of Navarre and member of the Nuclear Medicine Service of the University College Hospital of Navarre, has implemented 12 algorithms to process medical images produced by means of PET (Positron Emission Tomography).

13 Jun 2013

3D motion-tracked PET imaging uses MR micro-coils to reduce movement-related imaging artifacts

One of the biggest hurdles of hybrid positron emission tomography and magnetic resonance imaging is the prevalence of motion artifacts-blurring and ghostly visual anomalies caused by patient motion on the table during imaging.

13 Jun 2013

PET technique detects coronary disease much earlier than other leading imaging methods

Coronary artery disease (CAD) is one of the world's most prevalent and silent killers. Positron emission tomography (PET), which images miniscule abnormalities in cellular metabolism, can tip off clinicians about cardiac disasters waiting to happen- including sudden death from a heart attack-better than standard angiography, researchers revealed at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

12 Jun 2013

Hypometabolism in brain regions of cognitively normal patients associated with Alzheimer's disease

Alzheimer's disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer's disease-even for people with no sign of cognitive decline.

12 Jun 2013

New imaging system combines PET and MR for mapping recurrent prostate cancer

When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to plan the best possible treatment.

12 Jun 2013

Positron Emission Tomography News and Research

Patient-relevant benefit of PET or PET/CT in oesophageal cancer is still unclear

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Dopamine responses to alcohol ingestion may serve as marker of vulnerability to AUDs

Alcohol use increases risk of dopamine response in brain pathway

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Glucose intolerance, insulin resistance not associated with pathological features of AD

Long-term cannabis use, dopamine and motivation: an interview with Dr Michael Bloomfield, Department of Medicine at Imperial

Zecotek partners with Hamamatsu to commercialize existing imaging technologies

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

Pretreatment PET staging of LS-SCLC associated with improved survival

Study finds PTSD as risk factor for heart disease among Vietnam vets

Radionuclide drug treatment planning goes to next level with 3-D patient models

Researcher improves segmentation technique of PET images

3D motion-tracked PET imaging uses MR micro-coils to reduce movement-related imaging artifacts

PET technique detects coronary disease much earlier than other leading imaging methods

Hypometabolism in brain regions of cognitively normal patients associated with Alzheimer's disease

New imaging system combines PET and MR for mapping recurrent prostate cancer

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News